About us

Pursuing innovative research, medical discoveries, and drug therapies that benefit patients.
scientists at work

Leading the way

Sanford Burnham Prebys has deep expertise in fundamental biology and one of the most comprehensive drug discovery centers in the nonprofit world that accelerates the translation of our discoveries toward patient benefit.

47+ years

of pioneering research

Our mission

We conduct world-class collaborative research dedicated to finding cures for human disease, improving quality of life, and educating and training the next generation of scientists, thus creating a legacy for its employees, partners, donors and community.

How we aim to improve human health

Sanford Burnham Prebys is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. The Institute takes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration and infectious, inflammatory and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies.
Sanford Burnham Prebys is a U.S.-based, non-profit public benefit corporation based in San Diego (La Jolla), California.

Who we are

  • Sanford Burnham Prebys discoveries begin with our people – scientists, postdoctoral candidates, graduate students and support staff – who work collaboratively toward understanding the cause of disease and identifying new therapeutic approaches to improve human health.
  • As an independent, nonprofit institution, we focus on conducting biomedical research in cancer, neuroscience, immunology and rare children’s diseases.
  • The Institute is home to one of the most comprehensive drug discovery centers in the nonprofit world.
  • Our innovative approach to research underpins our strategic partnerships with the biotech and pharmaceutical industry.
  • We cultivate the next generation of biomedical scientists through our graduate and postdoctoral training programs.
Sanford Burnham Prebys employs more than 500 scientists and staff in San Diego (La Jolla), CA. We are widely recognized for our NCI-designated Cancer Center, the Conrad Prebys Center for Chemical Genomics and the Sanford Children’s Health Research Center.
Asset 1

Our approach to improving human health is built on three principles

Fundamental Research

Our track record of pioneering research spans more than 47 years, and has produced breakthrough discoveries in cancer, neuroscience, immunology and rare children's diseases.

Learn More

Drug Discovery

We operate one of the most advanced drug discovery centers in the world that leverages biomedical discoveries to develop prototype drugs. And our deep culture of collaboration has attracted a global network of passionate partners.

Learn More


We're committed to educating and training the next generation of scientific leaders to ensure our legacy continues.

Learn More


Author Correction: Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis.

Madaro L, Passafaro M, Sala D, Etxaniz U, Lugarini F, Proietti D, Alfonsi MV, Nicoletti C, Gatto S, De Bardi M, Rojas-García R, Giordani L, Marinelli S, Pagliarini V, Sette C, Sacco A, Puri PL

Nat Cell Biol 2024 Feb 7 ;

Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.

Abla O, Ries RE, Triche TJ Jr, Gerbing RB, Hirsch B, Raimondi S, Cooper TM, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo T, Meshinchi S

Blood Adv 2024 Feb 2 ;

Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes.

Gamez M, Elhegni HE, Fawaz S, Ho KH, Campbell NW, Copland DA, Onions KL, Butler MJ, Wasson EJ, Crompton M, Ramnath RD, Qiu Y, Yamaguchi Y, Arkill KP, Bates DO, Turnbull JE, Zubkova OV, Welsh GI, Atan D, Satchell SC, Foster RR

Cardiovasc Diabetol 2024 Feb 1 ;23(1):50

Rescuing lung development through embryonic inhibition of histone acetylation.

Stokes G, Li Z, Talaba N, Genthe W, Brix MB, Pham B, Wienhold MD, Sandok G, Hernan R, Wynn J, Tang H, Tabima DM, Rodgers A, Hacker TA, Chesler NC, Zhang P, Murad R, Yuan JX, Shen Y, Chung WK, McCulley DJ

Sci Transl Med 2024 Jan 31 ;16(732):eadc8930

TXNRD1 drives the innate immune response in senescent cells with implications for age-associated inflammation.

Hao X, Zhao B, Towers M, Liao L, Monteiro EL, Xu X, Freeman C, Peng H, Tang HY, Havas A, Kossenkov AV, Berger SL, Adams PD, Speicher DW, Schultz D, Marmorstein R, Zaret KS, Zhang R

Nat Aging 2024 Jan 24 ;

Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanisms.

Mealka M, Sierra NA, Matteo DA, Albekioni E, Khoury R, Mai T, Conley BM, Coleman NJ, Sabo KA, Komives EA, Bobkov AA, Cooksy AL, Silletti S, Schiffer JM, Huxford T, Sohl CD

bioRxiv 2024 Jan 23 ;

Show All Publications